Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer.
Geijerman E, Terrana F, Peters GJ, Deng D, Diana P, Giovannetti E, Xu G. Geijerman E, et al. Among authors: diana p. Expert Opin Investig Drugs. 2024 Nov;33(11):1103-1118. doi: 10.1080/13543784.2024.2417762. Epub 2024 Oct 22. Expert Opin Investig Drugs. 2024. PMID: 39435477 Free article. Review.
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C. Passiglia F, et al. Among authors: diana p. Expert Opin Investig Drugs. 2016;25(4):385-92. doi: 10.1517/13543784.2016.1152261. Epub 2016 Feb 24. Expert Opin Investig Drugs. 2016. PMID: 26881293 Review.
Pharmacogenetics of treatments for pancreatic cancer.
El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E. El Hassouni B, et al. Among authors: diana p. Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):437-447. doi: 10.1080/17425255.2019.1620731. Epub 2019 May 24. Expert Opin Drug Metab Toxicol. 2019. PMID: 31100206 Review.
Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells.
Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E. Li Petri G, et al. Among authors: diana p. Anticancer Res. 2019 Jul;39(7):3615-3620. doi: 10.21873/anticanres.13509. Anticancer Res. 2019. PMID: 31262887
3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma.
Cascioferro S, Li Petri G, Parrino B, El Hassouni B, Carbone D, Arizza V, Perricone U, Padova A, Funel N, Peters GJ, Cirrincione G, Giovannetti E, Diana P. Cascioferro S, et al. Among authors: diana p. Molecules. 2020 Jan 14;25(2):329. doi: 10.3390/molecules25020329. Molecules. 2020. PMID: 31947550 Free PMC article.
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
Cascioferro S, Petri GL, Parrino B, Carbone D, Funel N, Bergonzini C, Mantini G, Dekker H, Geerke D, Peters GJ, Cirrincione G, Giovannetti E, Diana P. Cascioferro S, et al. Among authors: diana p. Eur J Med Chem. 2020 Mar 1;189:112088. doi: 10.1016/j.ejmech.2020.112088. Epub 2020 Jan 25. Eur J Med Chem. 2020. PMID: 32007666
267 results